Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201302-01 Non-clinical development of Q203: A novel drug candidate against MDR/XDR tuberculosis(Infectious Diseases, Chemical) [05.06.2013]

PRINT

Development and Market Objectives

Completion of preclinical trials and entering phase 1 clinical trial for the development of a novel drug candidate against MDR(Multi Drug Resistant)/XDR(Extensively Drug Resistant) tuberculosis.

Unmet Medical Need & Target Patients

Target Patient Group
Patients infected with MDR/XDR tuberculosis bacillus who are not receiving first or second line standard medication.

Patients infected with TB which has susceptibility to existing drugs.
 
Unmet Medical Needs
Tuberculosis (TB) is a common infectious disease worldwide. TB infection has been challenging to control due to concurrent infections with HIV/AIDS and the rapid emergence of multi-drug resistant/extensively drug resistant (MDR/XDR) tuberculosis bacillus, despite continuous improvements in medical treatment and health care management systems.

According to a WHO and TB alliance report, two billion people, one-third of world’s population, are thought to have been infected by tuberculosis bacillus. In 2010, there were an estimated 1.4 million associated deaths.

The development of novel drugs has been delayed largely because tuberculosis has been regarded as a third world disease for the last fifty years. In addition, the market attractiveness for pharmas has been low due to low cost historical medicines such as isoniazid. However, the overall market size of anit-tuberculosis drugs is rapidly increasing  due to economic growth in high burden countries including China, India and Russia The need for novel drugs against MDR/XDR tuberculosis is also increasing due a growing incidence rate of MDR/XDR TB in Western countries,.
 

Status

Q203 has shown strong efficacy in TB animal model.
Q203 has shown strong bactericidal efficacy against MDR/XDR TB in  clinical isolates.
The mechanism of action - targeting the QcrB subunit of the cytochrome bc1 complex in the TB electron transfer system has been identified.
Q203 has been shown safety through preliminary toxicity tests in rodent and non-rodnet species.
 
Preclinical studies are now in progress to support human clinical study.

Intellectual Property

No. Patent Title Published to Publication Date Published to Publication Number
1 ANTI-INFECTIVE COMPOUNDS PCT 2011/03/11 PCT  
PCT/EP2011/001345

Competitive Advantages

First-in-Class: Q203 has novel mechanisms of action and inhibits the cytochrome bc1 complex and ATP synthesis in TB.
 
Strong efficacy: Even at low concentrations, Q203 exhibits strong efficacy in chronic tuberculosis experimental models. Low dosages of the compound are sufficient for effective treatment.
 
Efficacy against resistant strains: The candidate has proven its strong efficacy against MDR/EDR TB using clinical isolates.
 
High selectivity: Q203 has high selectivity against TB and minimizes side-effects such as eneteric bacterium elimination.
 
Improvement of quality of life for patients: Q203 has been proven to reduce post-infection inflammation via animal testing and minimizes lung damage.
 
Medical cost reduction: A short synthesis pathway enables significant reductions for the cost of production and its related expenses.

Indication

MDR/XDR tuberculosis

Research Period

May. 01, 2013 ~ Dec. 30, 2014

Company

Qurient Co. Ltd.

Developmental Stage

Non-clinical study

Additional Information

Contact Information

Contact
Address Company Name: Qurient
WebSite Homepage: http://www.qurient.com Contact Person: June Kim
E-mail: jkim@qurient.com Contact: 82-31-8018-8351

Related Projects

Related Project
Phase 1 Clinical development of Q203 : A novel drug candidate against MDR/XDR tuberculosis Project view
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code